Has Richard Flowers, MD received payments from drug or device companies?

Yes. Drug and device makers reported $11,017 in general payments to Richard Flowers, MD across 17 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Richard Flowers, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Richard Flowers, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Richard Flowers, MD

Dermatology · Charlottesville, VANPI 1467847541

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,560 of the $11,017 with a category attached, or 86.8%. Argenx US, Inc. accounts for 65.5% of it on its own, with 4 other manufacturers making up the rest. 2023 is the largest year on record at $10,852, more than ten times the $96 reported in 2019.

$11,017in general payments, 2019–2025

Across 17 payments — averaging $648.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Argenx US, Inc.$7K
E.r. Squibb & Sons, L.L.C.$2K
Johnson & Johnson$2K
AbbVie$96
Pfizer$30

$128,616in research payments, 2019–2025

Across 35 payments — averaging $3674.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sun Pharmaceutical Industries Inc.$57K
AbbVie$53K
Astrazeneca UK Limited$15K
Regeneron$3K

What the payments were for

Consulting fees$9,56087%
Travel & lodging$9619%
Food & beverage$3463%
Education$1501%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Argenx US, Inc.	10	$7,212
E.r. Squibb & Sons, L.L.C.	1	$2,170
Johnson & Johnson	3	$1,510
AbbVie	1	$96
Pfizer	2	$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VYVGART$7,060
Tremfya$1,390

How this compares

$11,017 in reported general payments places this provider in the 85th percentile of 396 dermatology providers in Virginia.

See all dermatology providers in Virginia →

Medicare billing

Part B allowed, 2024

$154,499

Medicare patients

924

Services billed

3,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Cosentyx Unoready PenSecukinumab	62	$646,790
Humira(Cf) PenAdalimumab	39	$626,775
Dupixent PenDupilumab	43	$166,914
Dupixent SyringeDupilumab	40	$150,603
RinvoqUpadacitinib	16	$119,420
Acitretin	27	$17,833
Mycophenolate Mofetil	31	$15,562
Clobetasol Propionate	108	$7,174
ErtapenemErtapenem Sodium	22	$5,686
Tretinoin	40	$3,183
Tacrolimus	33	$2,046
Triamcinolone Acetonide	100	$1,419
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc	11	$1,189
Clindamycin Phosphate	33	$1,161
Fluorouracil	12	$1,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieRinvoq	$96	$119,42016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 396 dermatology providers in Virginia.

Other dermatology in Charlottesville

Anna MageeCharlottesville$37K
Christopher ScottCharlottesville$32K
Smitha KuppalliCharlottesville$15K
Naiem IssaVienna$2M
Saurabh SinghFairfax$1.7M
Diego DasilvaVirginia Beach$1.1M
Vishal PatelLeesburg$719K
Cyndi Torosky TommasoVirginia Beach$717K
Daniel HurdBlacksburg$545K
Jonathan SchreiberNorfolk$330K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →